NS 360, INC. – Trademark Portfolio

Entity Type: 03

NS 360, INC. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 14 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 3 are pending. Notable registered marks include CILTEP, MAGTECH, and SMART CAFFEINE. The owner is based in WILMINGTON, DE.

CORPORATION TRUST CENTER 1209 ORANGE

ST.

WILMINGTON, DE 19801

18 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

NS 360, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (14 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (4 filings)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does NS 360, INC. have?

NS 360, INC. has 18 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 pending, 8 abandoned, 4 cancelled.

What trademark classes does NS 360, INC. file in?

NS 360, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are NS 360, INC.'s most well-known trademarks?

NS 360, INC.'s registered trademark portfolio includes well-known marks such as CILTEP, MAGTECH, and SMART CAFFEINE. These are among 3 currently registered trademarks in the portfolio.

What is NS 360, INC.'s trademark registration success rate?

NS 360, INC. has a 20% trademark registration rate, with 3 out of 15 resolved applications resulting in successful registration. Currently, 3 applications are pending review.